Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016
Graham CN, Davis KL, Goyal RK. Effect of sample size and data maturity on parametric survival modeling projections in advanced cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Graham CN, Hechmati G, Hjelmgren J, de Liege F, Knoof A, Lanier J, Knox HN, Barber B, de Pouvourville G. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type ras metastatic colorectal cancer. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.